The focus of this research is to define immunologic and other cofactors to explain why cervical HPV infection (a common sexually-transmitted diseases) progresses in rare instances to high-grade neoplasia. Accompanying prevention research on HPV immunology attempts to complement ongoing worldwide vaccine development efforts by suggesting biomarkers correlated with good clinical outcomes following infection (i.e., natural protection). Several immunology projects were completed. A large, cross-sectional investigation of cellular immune responses to the transforming proteins of HPV (E6 and E7) demonstrated that women with serious neoplasia had lower IL-2 production than HPV-infected women who did not develop serious neoplasia. Thus, high IL-2 production might be a useful marker of successful host control of HPV infection (the """"""""Th1 response""""""""). With regard to serologic measurements of immune response, the virus-like particle (VLP) assay was confirmed to be a useful epidemiologic biomarker of infection. Although not as sensitive as DNA testing for current infection, the VLP assay permits some measurement of infections no longer detectable by HPV DNA testing. Thus, an examination of VLP seropositivity among HPV DNA-negative women demonstrated a strong association with past sexual activity. HPV serology can now be used in studies where tissue specimens are not available. In a study in China, penile cancer was found not to be HPV-related. In the U.S., vulvar cancer was shown to be divisible into HPV-related and non-related histologic subtypes. Serology tests suggested that there are at least two distinct patterns of responses to HPV among women with cervical neoplasia. Serologic and cellular assays are now being tested in prospective studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CP010124-01
Application #
2456747
Study Section
Special Emphasis Panel (EEB)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Division of Cancer Epidemiology and Genetics
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Litwin, Tamara R; Clarke, Megan A; Dean, Michael et al. (2017) Somatic Host Cell Alterations in HPV Carcinogenesis. Viruses 9:
Wentzensen, Nicolas; Arbyn, Marc; Berkhof, Johannes et al. (2017) Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer 140:2192-2200
Eldridge, Ronald C; Pawlita, Michael; Wilson, Lauren et al. (2017) Smoking and subsequent human papillomavirus infection: a mediation analysis. Ann Epidemiol 27:724-730.e1
Castro, Felipe A; Koshiol, Jill; Quint, Wim et al. (2015) Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infect Dis 15:544
Chaux, Alcides; Netto, George J; Rodríguez, Ingrid M et al. (2013) Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol 31:861-7
Castle, Philip E; Shaber, Ruth; LaMere, Brandon J et al. (2011) Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev 20:946-53
Castle, Philip E; Gage, Julia C; Wheeler, Cosette M et al. (2011) The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol 118:1222-9
Kinney, Walter; Fetterman, Barbara; Cox, J Thomas et al. (2011) Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol 121:309-13
Castle, Philip E; Rausa, Alfio; Walls, Tameka et al. (2011) Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med 52:452-5
Galgano, Mary T; Castle, Philip E; Atkins, Kristen A et al. (2010) Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 34:1077-87

Showing the most recent 10 out of 72 publications